Background: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana®), hormonal agents abiraterone (Zytiga®) and...

Purpose/Objectives: To develop a better understanding of how older adult survivors of early-stage breast and prostate cancer managed the work of recovery. Research Approach: Multiple case study design embedded in a larger randomized, controlled trial of a nurse-led patient navigation intervention...

Purpose/Objectives: To examine partner involvement in treatment decision making for localized prostate cancer, congruence between partner involvement and patient preference, reasons for partner noninvolvement, and partner satisfaction with patient treatment. Design: Cross-sectional exploratory...

Purpose/Objectives: To determine whether exercise could reduce biomarkers of cancer progression in prostate cancer survivors (PCSs) on androgen-deprivation therapy (ADT). Design: Randomized, controlled trial. Setting: Oregon Health and Science University School of Nursing. Sample: 51 PCSs...